My laboratory is involved in clinical and translational research program in multiple sclerosis (MS) therapeutics.
My laboratory has investigated the neuroimmunological and genomic mechanisms that contribute to the heterogeneity of clinical treatment responses for this chronic, disabling neurological disease. Currently, the broad focus of my MS research is to delineate the interactions among patient-specific, environmental and genetic factors that contribute to inter-individual differences in disease progression.
We employ a unique multi-disciplinary approach to research by leveraging our strengths in pharmaceutical sciences and bioengineering and also through my productive collaborations with scientists from clinical disciplines such as neurologists, neuroradiologists, neuropsychologists and also from quantitative disciplines such computer science and biostatistics. Through these collaborations, our group has been able take on challenging scientific problems that could not be undertaken by any one of us individually.
My multi-disciplinary research spans two inter-related areas: i) clinical research on the roles of environmental factors in MS progression and, ii) molecular and quantitative clinical pharmacology.
My recent work has focused on cholesterol and lipid biomarkers in multiple sclerosis disease progression. My group has investigated other compelling environmental factors in MS including immune responses to Epstein-Barr virus exposure, vitamin D metabolism and smoking. I have the necessary expertise and record in quantitating environmental factors and surrogate markers in MS.
We also have extensive experience in pharmaceutical applications of "big data" and modeling analysis of large high-dimensional data sets containing environmental factors, genetic and immunological biomarkers, quantitative neuroimaging metrics and clinical measures in MS.
If you wish to support Dr. Ramanathan‘s multiple sclerosis research with a contribution, please visit his research giving form